EPIRUBICIN HYDROCHLORIDE INJECTION SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

EPIRUBICIN HYDROCHLORIDE

متاح من:

FRESENIUS KABI CANADA LTD

ATC رمز:

L01DB03

INN (الاسم الدولي):

EPIRUBICIN

جرعة:

2.0MG

الشكل الصيدلاني:

SOLUTION

تركيب:

EPIRUBICIN HYDROCHLORIDE 2.0MG

طريقة التعاطي:

INTRAVENOUS

الوحدات في الحزمة:

5ML/25ML/100ML

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

ANTINEOPLASTIC AGENTS

ملخص المنتج:

Active ingredient group (AIG) number: 0116901002; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2008-12-04

خصائص المنتج

_ _
_ _
PRODUCT MONOGRAPH
STERILE
PR
EPIRUBICIN HYDROCHLORIDE INJECTION
(Epirubicin Hydrochloride)
2 mg/mL
Mfr. Standard
ANTINEOPLASTIC AGENT
FRESENIUS KABI CANADA LTD.
Date of Revision:
45 Vogell Road, Suite 200
January 9, 2017
Richmond Hill, ON L4B 3P6
Submission Control No.: 201601
_Epirubicin Hydrochloride-PM-Eng-v2.0 _
_ _
_ _
_ _
_ _
_ _
_ Page 2 of 38 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
14
OVERDOSAGE
...............................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 18
STORAGE AND STABILITY
.........................................................................................
19
SPECIAL HANDLING INSTRUCTIONS
......................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 21
PART II: SCIENTIFIC INFORMATION
...............................................................................
23
PHARMACEUTICAL INFORMATION
.........................................................................
23
CLINICAL TRIALS
...............